Olink

Olink®
Part of Thermo Fisher Scientific

Targeted serum proteome profiling reveals nicotinamide adenine dinucleotide phosphate (NADPH)-related biomarkers to discriminate linear IgA bullous disorder from dermatitis herpetiformis

Clinical Immunology, 2024

Wang T., Li L., Cao S., Sun L., Yu G., Xia Q., Liu T., Zhao Q., Wang Z., Wang C., Yang B., Liu Y., Chen X., Chen S., Zhou G., Liu H., Sun Y., Zhang F.

Disease areaApplication areaSample typeProducts
Immunological & Inflammatory Diseases
Dermatological Diseases
Pathophysiology
Patient Stratification
Serum
Olink Target 96

Olink Target 96

Abstract

Linear IgA bullous dermatosis (LABD) and dermatitis herpetiformis (DH) represent the major subtypes of IgA mediated autoimmune bullous disorders. We sought to understand the disease etiology by using serum proteomics. We assessed 92 organ damage biomarkers in LABD, DH, and healthy controls using the Olink high-throughput proteomics. The positive proteomic serum biomarkers were used to correlate with clinical features and HLA type. Targeted proteomic analysis of IgA deposition bullous disorders vs. controls showed elevated biomarkers. Further clustering and enrichment analyses identified distinct clusters between LABD and DH, highlighting the involvement of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Comparative analysis revealed biomarkers with distinction between LABD and DH and validated in the skin lesion. Finally, qualitative correlation analysis with DEPs suggested six biomarkers (NBN, NCF2, CAPG, FES, BID, and PXN) have better prognosis in DH patients. These findings provide potential biomarkers to differentiate the disease subtype of IgA deposition bullous disease.

Read publication ↗